ReviewHuman vaccines & immunotherapeutics2013
Intanza (®) 9 µg intradermal seasonal influenza vaccine for adults 18 to 59 years of age.
Review in Human vaccines & immunotherapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Assessing the integrity and mechanical properties of commercial microneedles: innovation or fad?Drug delivery and translational research · 2025Article
- Immunogenicity, safety and tolerability of intradermal influenza vaccines.Human vaccines & immunotherapeutics · 2018Review
- Intradermal delivery of a fractional dose of influenza H7N9 split vaccine elicits protective immunity in mice and rats.Human vaccines & immunotherapeutics · 2018Article
- Challenges and Future Prospects for the Delivery of Biologics: Oral Mucosal, Pulmonary, and Transdermal Routes.The AAPS journal · 2017Article
- The success of microneedle-mediated vaccine delivery into skin.Human vaccines & immunotherapeutics · 2016Review
- Fluzone® intra-dermal (Intanza®/Istivac® Intra-dermal): An updated overview.Human vaccines & immunotherapeutics · 2016Review
- Intradermal vaccination for infants and children.Human vaccines & immunotherapeutics · 2016Review
- Intradermal vaccination using the novel microneedle device MicronJet600: Past, present, and future.Human vaccines & immunotherapeutics · 2015Review
- Adverse events after Fluzone ® Intradermal vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2011-2013.Vaccine · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Seasonal influenza in healthy working-age adults accounts for a substantial part of the socioeconomic burden of this disease. Intanza® 9 µg (sanofi pasteur) is a microneedle-delivered intradermal trivalent inactivated influenza vaccine approved in 2009 for the prevention of seasonal influenza in adults 18 to 59 years of age. The microneedle system reliably and reproducibly delivers the vaccine to the dermis. Clinical studies show that Intanza 9 µg is as immunogenic and as well tolerated in working-age adults as a reference intramuscular trivalent inactivated vaccine. Local reactions to Intanza 9 µg, mainly erythema, are transient, mostly mild or moderate, and do not affect acceptability. Intanza 9 µg is considered satisfactory by at least 95% of both vaccinees and prescribers, especially because of the short needle and rapid administration. Because Intanza® 9 µg offers an alternative to intramuscular vaccines, it might help increase influenza vaccine coverage rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.